Since taking over as CEO of the Cambridge biotech more than three years ago, Chris Viehbacher has cut hundreds of jobs and reduced expenses, in part by removing drugs from its research pipeline.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results